Mind Medicine (MindMed) Inc. (E:MMED*CA)

Business Focus: Biotechnology & Medical Research (NEC)

Nov 16, 2021 06:30 am ET
MindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive Measures
NEW YORK, Nov. 16, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD; NEO: MMED; DE: MMQ; the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce it has launched recruitment for a randomized placebo-controlled study evaluating the effects of daytime and evening administration of repeated low doses of LSD (the "LSD Study").
Nov 16, 2021 06:30 am ET
MindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive Measures
NEW YORK, Nov. 16, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD; NEO: MMED; DE: MMQ; the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce it has launched recruitment for a randomized placebo-controlled study evaluating the effects of daytime and evening administration of repeated low doses of LSD (the "LSD Study").
Nov 15, 2021 06:30 am ET
MindMed Announces Financial Results for the Third Quarter 2021 and Business Highlights; Cash Balance of $145.9 USD ($185.4 CAD) to Execute on Diverse Clinical Pipeline
NEW YORK, Nov. 15, 2021 /PRNewswire/ -- MindMed (Nasdaq: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, has announced its quarterly financial results for the quarter ended September 30, 2021.
Nov 15, 2021 06:30 am ET
MindMed Announces Financial Results for the Third Quarter 2021 and Business Highlights; Cash Balance of $145.9 USD ($185.4 CAD) to Execute on Diverse Clinical Pipeline
NEW YORK, Nov. 15, 2021 /CNW/ -- MindMed (Nasdaq: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, has announced its quarterly financial results for the quarter ended September 30, 2021.
Nov 12, 2021 06:30 am ET
MindMed to Present at the Jefferies London Healthcare Conference
NEW YORK, Nov. 12, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that its CEO, Robert Barrow, will be speaking at Jefferies 2021 London Healthcare Conference, taking place on November 16-19. Management will be available during the conference for in-person and virtual one-on-one meetings.
Nov 12, 2021 06:30 am ET
MindMed to Present at the Jefferies London Healthcare Conference
NEW YORK, Nov. 12, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that its CEO, Robert Barrow, will be speaking at Jefferies 2021 London Healthcare Conference, taking place on November 16-19. Management will be available during the conference for in-person and virtual one-on-one meetings.
Nov 05, 2021 07:30 am ET
MindMed Appoints Dr. Maria Oquendo to its Scientific Advisory Board
NEW YORK, Nov. 5, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the appointment of Maria A. Oquendo, M.D., Ph.D. to its Scientific Advisory Board.
Nov 05, 2021 07:30 am ET
MindMed Appoints Dr. Maria Oquendo to its Scientific Advisory Board
NEW YORK, Nov. 5, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the appointment of Maria A. Oquendo, M.D., Ph.D. to its Scientific Advisory Board.
Nov 01, 2021 07:30 am ET
MindMed to Present at Web Summit on Future of Mental Health
NEW YORK, Nov. 1, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that CEO Robert Barrow will be speaking at Web Summit, taking place on November 1-4, 2021 in Lisbon, Portugal.
Nov 01, 2021 07:30 am ET
MindMed to Present at Web Summit on Future of Mental Health
NEW YORK, Nov. 1, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that CEO Robert Barrow will be speaking at Web Summit, taking place on November 1-4, 2021 in Lisbon, Portugal.
Oct 26, 2021 07:00 am ET
MindMed Expands its Drug Development Pipeline with Launch of R(-)-MDMA Program
NEW YORK, Oct. 26, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED), (DE: MMQ); the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce an expansion of its pipeline with the launch of a program to develop R(-)-MDMA for the treatment of social anxiety and functioning in diagnoses that include Autism Spectrum Disorder (ASD).  This program represents a significant expansion and diversification of MindMed's pipeline and furthers the Company's mission to bring innovative products to benefit patients and address unmet
Oct 26, 2021 07:00 am ET
MindMed Expands its Drug Development Pipeline with Launch of R(-)-MDMA Program
NEW YORK, Oct. 26, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED), (DE: MMQ); the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce an expansion of its pipeline with the launch of a program to develop R(-)-MDMA for the treatment of social anxiety and functioning in diagnoses that include Autism Spectrum Disorder (ASD).  This program represents a significant expansion and diversification of MindMed's pipeline and furthers the Company's mission to bring innovative products to benefit patients and address unmet medical
Oct 25, 2021 07:30 am ET
MindMed CMO to Chair Digital Biomarkers Summit
NEW YORK, Oct. 25, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that Chief Medical Officer Daniel R Karlin, MD MA, will chair The Digital Biomarkers & Digital Measurements Summit, held virtually on October 26 - 27, 2021.
Oct 25, 2021 07:30 am ET
MindMed CMO to Chair Digital Biomarkers Summit
NEW YORK, Oct. 25, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that Chief Medical Officer Daniel R Karlin, MD MA, will chair The Digital Biomarkers & Digital Measurements Summit, held virtually on October 26 - 27, 2021.
Oct 13, 2021 07:30 am ET
MindMed Joins Clinical Trials Transformation Initiative
NEW YORK, Oct. 13, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has joined the Clinical Trials Transformation Initiative (CTTI) to contribute in developing and driving adoption of practices that increase the quality and efficiency of clinical trials.
Oct 13, 2021 07:30 am ET
MindMed Joins Clinical Trials Transformation Initiative
NEW YORK, Oct. 13, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has joined the Clinical Trials Transformation Initiative (CTTI) to contribute in developing and driving adoption of practices that increase the quality and efficiency of clinical trials.
Oct 05, 2021 07:30 am ET
MindMed Announces Strategic Research Collaboration with Sphere Health
NEW YORK, Oct. 5, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has agreed to partner with Sphere Health – a physician-founded employee benefits provider targeting treatments for people with severe mental illness – to collect and analyze multimodal data in order to improve the understanding of a variety of biomarkers associated with mental illnesses including anxiety and affective disorders.
Oct 05, 2021 07:30 am ET
MindMed Announces Strategic Research Collaboration with Sphere Health
NEW YORK, Oct. 5, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has agreed to partner with Sphere Health – a physician-founded employee benefits provider targeting treatments for people with severe mental illness – to collect and analyze multimodal data in order to improve the understanding of a variety of biomarkers associated with mental illnesses including anxiety and affective disorders.
Sep 30, 2021 07:30 am ET
MindMed Announces Appointment of Andreas Krebs and Carol Vallone as Directors and Transition of Bruce Linton
NEW YORK, Sept. 30, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) ("MindMed" or the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that its board of directors has appointed Mr. Andreas Krebs and Ms. Carol Vallone as directors of the Company, effective immediately.
Sep 30, 2021 07:30 am ET
MindMed Announces Appointment of Andreas Krebs and Carol Vallone as Directors and Transition of Bruce Linton
NEW YORK, Sept. 30, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) ("MindMed" or the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that its board of directors has appointed Mr. Andreas Krebs and Ms. Carol Vallone as directors of the Company, effective immediately.
Sep 29, 2021 07:30 am ET
MindMed Appoints University of North Carolina Psychiatrist and Pharmacologist Dr. Bryan Roth to Scientific Advisory Board
NEW YORK, Sept. 29, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the addition of Bryan L. Roth, MD, PhD to its Scientific Advisory Board.
Sep 29, 2021 07:30 am ET
MindMed Appoints University of North Carolina Psychiatrist and Pharmacologist Dr. Bryan Roth to Scientific Advisory Board
NEW YORK, Sept. 29, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the addition of Bryan L. Roth, MD, PhD to its Scientific Advisory Board.
Sep 28, 2021 07:30 am ET
MindMed to present at the Benzinga Healthcare Small Cap Conference
NEW YORK, Sept. 28, 2021 /PRNewswire/ -- (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that Robert Barrow, Chief Executive Officer of MindMed, will be speaking at the Benzinga Healthcare Small Cap Conference, taking place on September 29-30, 2021.
Sep 28, 2021 07:30 am ET
MindMed to present at the Benzinga Healthcare Small Cap Conference
NEW YORK, Sept. 28, 2021 /CNW/ -- (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that Robert Barrow, Chief Executive Officer of MindMed, will be speaking at the Benzinga Healthcare Small Cap Conference, taking place on September 29-30, 2021.
Sep 23, 2021 07:30 am ET
MindMed and Liechti Lab Provide Results from their Psilocybin R&D Collaboration
NEW YORK, Sept. 23, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that Dr. Matthias Liechti presented data from several ongoing studies at the INSIGHT Conference in Berlin, Germany. These investigator-initiated studies are being conducted as part of MindMed's ongoing collaboration with the UHB Liechti Lab.
Sep 21, 2021 07:30 am ET
MindMed Announces Participation at Upcoming Investor Conferences
NEW YORK, Sept. 21, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today announces that Robert Barrow, Chief Executive Officer of MindMed, will participate in the following investor conferences:
Sep 21, 2021 07:30 am ET
MindMed Announces Participation at Upcoming Investor Conferences
NEW YORK, Sept. 21, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today announces that Robert Barrow, Chief Executive Officer of MindMed, will participate in the following investor conferences:
Sep 10, 2021 07:30 am ET
MindMed to Present at H.C. Wainwright 23rd Annual Global Investment Conference
NEW YORK, Sept. 10, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that Robert Barrow, Chief Executive Officer of MindMed, will present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021. Members of management will also be available to speak with institutional investors in one-on-one virtual meetings throughout the conference.
Sep 10, 2021 07:30 am ET
MindMed to Present at H.C. Wainwright 23rd Annual Global Investment Conference
NEW YORK, Sept. 10, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that Robert Barrow, Chief Executive Officer of MindMed, will present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021. Members of management will also be available to speak with institutional investors in one-on-one virtual meetings throughout the conference.
Sep 09, 2021 07:30 am ET
MindMed to Attend 8th Annual "Mobile in Clinical Trials" Conference
NEW YORK, Sept. 9, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that its Chief Medical Officer, Daniel R. Karlin, MD MA, will co-chair the 8th annual Mobile in Clinical Trials Conference, which will be held virtually on September 27, 2021 and is a partner program to the 2021 DPharm Conference.
Sep 09, 2021 07:30 am ET
MindMed to Attend 8th Annual "Mobile in Clinical Trials" Conference
NEW YORK, Sept. 9, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that its Chief Medical Officer, Daniel R. Karlin, MD MA, will co-chair the 8th annual Mobile in Clinical Trials Conference, which will be held virtually on September 27, 2021 and is a partner program to the 2021 DPharm Conference.
Sep 02, 2021 07:30 am ET
MindMed and BioXcel Therapeutics Publish an International Patent Application Describing a System for Identifying Agitation Episodes
NEW YORK, Sept. 2, 2021 /CNW/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, and BioXcel Therapeutics, Inc. ("BioXcel"), a leading clinical-stage biopharmaceutical company, announce the publication of BioXcel's International Patent Application No. PCT/US2020/051256 (published as WO2021055595) for detecting and preventing the early onset of agitation in patients predisposed to highly agitated behaviour. The disclosure provides a method for measuring the signs of an impending agitation event and alerts the c
Sep 02, 2021 07:30 am ET
MindMed and BioXcel Therapeutics Publish an International Patent Application Describing a System for Identifying Agitation Episodes
NEW YORK, Sept. 2, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, and BioXcel Therapeutics, Inc. ("BioXcel"), a leading clinical-stage biopharmaceutical company, announce the publication of BioXcel's International Patent Application No. PCT/US2020/051256 (published as WO2021055595) for detecting and preventing the early onset of agitation in patients predisposed to highly agitated behaviour. The disclosure provides a method for measuring the signs of an impending agitation event and alert
Aug 24, 2021 07:30 am ET
MindMed Announces Collaboration With Forian To Advance Development Of Personalized Psychiatry For Anxiety Disorders
NEW YORK, Aug. 24, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has agreed to work with Forian Inc. (NASDAQ: FORA), a leading provider of evidence-based support for more comprehensive clinical and commercial decision-making.
Aug 24, 2021 07:30 am ET
MindMed Announces Collaboration With Forian To Advance Development Of Personalized Psychiatry For Anxiety Disorders
NEW YORK, Aug. 24, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has agreed to work with Forian Inc. (NASDAQ: FORA), a leading provider of evidence-based support for more comprehensive clinical and commercial decision-making.
Aug 17, 2021 07:30 am ET
MindMed Joins Critical Path Institute's Patient-Reported Outcome Consortium
NEW YORK, Aug. 17, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has joined the Critical Path Institute's ("C-Path's") Patient-Reported Outcome (PRO) Consortium to assist in the development of new approaches to advance medical innovation and regulatory science.
Aug 17, 2021 07:30 am ET
MindMed Joins Critical Path Institute's Patient-Reported Outcome Consortium
NEW YORK, Aug. 17, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has joined the Critical Path Institute's ("C-Path's") Patient-Reported Outcome (PRO) Consortium to assist in the development of new approaches to advance medical innovation and regulatory science.
Aug 12, 2021 11:50 pm ET
MindMed Announces 2021 Q2 Financial Results; Cash Balance of $157 USD Million ($195 CAD Million) to Execute on Diverse Clinical Pipeline
NEW YORK, Aug. 12, 2021 /CNW/ -- MindMed (Nasdaq: MNMD), (NEO: MMED), (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, has announced its quarterly financial results for the quarter ended June 30, 2021.
Aug 12, 2021 11:50 pm ET
MindMed Announces 2021 Q2 Financial Results; Cash Balance of $157 USD Million ($195 CAD Million) to Execute on Diverse Clinical Pipeline
NEW YORK, Aug. 12, 2021 /PRNewswire/ -- MindMed (Nasdaq: MNMD), (NEO: MMED), (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, has announced its quarterly financial results for the quarter ended June 30, 2021.
Aug 10, 2021 07:30 am ET
MindMed Appoints Dr. Robert Dworkin to Scientific Advisory Board
NEW YORK, Aug. 10, 2021 /CNW/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, announces the addition of Robert H. Dworkin, Ph.D. to its Scientific Advisory Board.
Aug 10, 2021 07:30 am ET
MindMed Appoints Dr. Robert Dworkin to Scientific Advisory Board
NEW YORK, Aug. 10, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, announces the addition of Robert H. Dworkin, Ph.D. to its Scientific Advisory Board.
Aug 03, 2021 07:30 am ET
MindMed Joins Digital Medicine Society to Improve Health Outcomes and Equity Using Technology
NEW YORK, Aug. 3, 2021 /CNW/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, announced today that it will participate in and financially support the Digital Medicine Society's (DiMe) Digital Health Measurement Collaborative Community (DATAcc), an effort to develop best practices and streamline the medical field's approaches to measuring health using digital technologies.
Aug 03, 2021 07:30 am ET
MindMed Joins Digital Medicine Society to Improve Health Outcomes and Equity Using Technology
NEW YORK, Aug. 3, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, announced today that it will participate in and financially support the Digital Medicine Society's (DiMe) Digital Health Measurement Collaborative Community (DATAcc), an effort to develop best practices and streamline the medical field's approaches to measuring health using digital technologies.
Jul 28, 2021 07:00 am ET
MindMed Announces Initiation of Phase 1 Clinical Trial of Intravenous DMT
NEW YORK, July 28, 2021 /CNW/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the start of a Phase 1 clinical trial to assess the safety, pharmacokinetics and pharmacodynamics of DMT, a naturally occurring psychedelic substance and an active ingredient in ayahuasca. The outcome of this Phase 1 clinical trial is expected to facilitate potential future Phase 2 clinical trials of DMT in patients. The clinical trial is being conducted as an investigator-initiated study by Dr. Matthias Liechti as part of
Jul 28, 2021 07:00 am ET
MindMed Announces Initiation of Phase 1 Clinical Trial of Intravenous DMT
NEW YORK, July 28, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the start of a Phase 1 clinical trial to assess the safety, pharmacokinetics and pharmacodynamics of DMT, a naturally occurring psychedelic substance and an active ingredient in ayahuasca. The outcome of this Phase 1 clinical trial is expected to facilitate potential future Phase 2 clinical trials of DMT in patients. The clinical trial is being conducted as an investigator-initiated study by Dr. Matthias Liechti as p
Jul 12, 2021 07:30 am ET
MindMed Chosen to Participate in Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit
NEW YORK, July 12, 2021 /CNW/ -- MindMed (NASDAQ: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that MindMed's Chief Executive Officer, Robert Barrow, will be leading a roundtable discussion at Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit.
Jul 12, 2021 07:30 am ET
MindMed Chosen to Participate in Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit
NEW YORK, July 12, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that MindMed's Chief Executive Officer, Robert Barrow, will be leading a roundtable discussion at Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit.
Jul 08, 2021 08:20 am ET
MindMed Announces Partnership with Datavant, a Leading Health Data Connectivity Company
NEW YORK, July 8, 2021 /CNW/ -- MindMed (Nasdaq: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, and Datavant, Inc. ("Datavant"), a leader in helping healthcare organizations safely connect their data, announced a partnership through which MindMed will use Datavant's privacy-protecting technology to link MindMed's clinical trial data to external data from both clinical and real-world sources.  MindMed plans to use Datavant's linking technology across various stages of the drug lifecycle including discovery, clinical development, and commerciali
Jul 08, 2021 08:20 am ET
MindMed Announces Partnership with Datavant, a Leading Health Data Connectivity Company
NEW YORK, July 8, 2021 /PRNewswire/ -- MindMed (Nasdaq: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, and Datavant, Inc. ("Datavant"), a leader in helping healthcare organizations safely connect their data, announced a partnership through which MindMed will use Datavant's privacy-protecting technology to link MindMed's clinical trial data to external data from both clinical and real-world sources.  MindMed plans to use Datavant's linking technology across various stages of the drug lifecycle including discovery, clinical development, and comm
Jun 28, 2021 07:30 am ET
MindMed Included in FTSE Russell 3000® Index
NEW YORK, June 28, 2021 /CNW/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic-inspired medicine company announced that effective Friday, June 25th, 2021, MindMed has been added to the FTSE Russell 3000® index which measures the performance of the largest 3,000 US companies.
Jun 28, 2021 07:30 am ET
MindMed Included in FTSE Russell 3000® Index
NEW YORK, June 28, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic-inspired medicine company announced that effective Friday, June 25th, 2021, MindMed has been added to the FTSE Russell 3000® index which measures the performance of the largest 3,000 US companies.
Jun 23, 2021 07:30 am ET
MindMed Appoints MGH Psychiatrist-in-Chief Dr. Maurizio Fava to Scientific Advisory Board
NEW YORK, June 23, 2021 /CNW/ -- MindMed (Nasdaq: MNMD) (NEO: MMED) (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has announced the addition of Dr. Maurizio Fava, a world-leading expert in psychiatry and psychiatric clinical trials from Massachusetts General Hospital and the Harvard Medical School to the Company's Scientific Advisory Board.
Jun 23, 2021 07:30 am ET
MindMed Appoints MGH Psychiatrist-in-Chief Dr. Maurizio Fava to Scientific Advisory Board
NEW YORK, June 23, 2021 /PRNewswire/ -- MindMed (Nasdaq: MNMD) (NEO: MMED) (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has announced the addition of Dr. Maurizio Fava, a world-leading expert in psychiatry and psychiatric clinical trials from Massachusetts General Hospital and the Harvard Medical School to the Company's Scientific Advisory Board.
Jun 17, 2021 07:30 am ET
MindMed Appoints Pharmaceutical Veteran Peter Bergethon, M.D. to Scientific Advisory Board
NEW YORK, June 17, 2021 /CNW/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has announced the addition of Dr. Peter Bergethon, a world-leading expert in neurology, digital medicine, and central nervous system (CNS) drug development to the Company's Scientific Advisory Board.
Jun 17, 2021 07:30 am ET
MindMed Appoints Pharmaceutical Veteran Peter Bergethon, M.D. to Scientific Advisory Board
NEW YORK, June 17, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has announced the addition of Dr. Peter Bergethon, a world-leading expert in neurology, digital medicine, and central nervous system (CNS) drug development to the Company's Scientific Advisory Board.
Jun 09, 2021 07:16 am ET
MindMed Announces Chief Executive Officer Transition
NEW YORK, June 9, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading clinical-stage pharmaceutical company and pioneer in the field of psychedelic inspired medicines, announces that J.R. Rahn, the Company's co-founder and chief executive officer, is stepping down as chief executive officer and a director, and that its chief development officer, Robert Barrow, will assume the position of chief executive officer with immediate effect. The Company will also initiate a comprehensive search for a chief executive officer, in which Mr. Barro
Jun 09, 2021 07:16 am ET
MindMed Announces Chief Executive Officer Transition
NEW YORK, June 9, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading clinical-stage pharmaceutical company and pioneer in the field of psychedelic inspired medicines, announces that J.R. Rahn, the Company's co-founder and chief executive officer, is stepping down as chief executive officer and a director, and that its chief development officer, Robert Barrow, will assume the position of chief executive officer with immediate effect. The Company will also initiate a comprehensive search for a chief executive officer, in which Mr
May 28, 2021 08:30 am ET
NEO Exchange Announces Eligibility In MSCI Indexes
NEO is proud to announce that MSCI Inc. (“MSCI”), a leading provider of critical decision support tools and services for the global investment community, now recognizes the NEO Exchange as an eligible market for inclusion in MSCI Indexes under the MSCI Global Investable Market Indexes Methodology.
May 27, 2021 06:30 pm ET
MindMed announces shareholder Meeting Results
NEW YORK, May 27, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) ("MindMed" or the "Company") is pleased to announce that each of the resolutions put before the annual and special meeting of shareholders held today (the "Meeting") was passed by the requisite majority of shareholders.
May 26, 2021 07:30 am ET
MindMed and Liechti Lab in Basel Switzerland Publish First Pharmacogenetic Data on LSD to Help Guide Personalized Dosing
NEW YORK, May 26, 2021 /CNW/ -- MindMed (Nasdaq: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic medicine biotech company, announced today the publication of the first pharmacogenetic data on LSD to help personalize dosing. The study results from a pooled secondary analysis of four Phase 1 studies that each used a randomized, double-blind, placebo-controlled, crossover design and were conducted at the University Hospital Basel Liechti Lab, in Basel, Switzerland.
May 24, 2021 07:30 am ET
MindMed Announces Launch of Collaboration with Nextage Therapeutics' Brain Targeting Liposome System
NEW YORK, May 24, 2021 /CNW/ -- MindMed (NASDAQ: MNMD, NEO: MMED, DE: MMQ), a leading clinical stage psychedelic medicine company, and Nextage Therapeutics (TASE: NXTG), an Israeli innovative drug development company, announce the execution of a Memorandum of Understanding (the "MOU") regarding the launch of an exclusive collaborative development program to optimize the delivery of certain psychedelic drug candidates, leveraging Nextage's proprietary Brain Targeting Liposome System (BTLS) delivery technology, for which it has an exclusive license.  MindMed and Nextage will initially collabor
May 20, 2021 07:30 am ET
MindMed Announces the Approval of Mescaline Study
BASEL, Switzerland, May 20, 2021 /CNW/ -- MindMed (Nasdaq: MNMD) (NEO: MMED) (DE: MMQ), a leading clinical stage psychedelic medicine company, announced today the approval by the local Swiss ethics committee of the first clinical trial evaluating the acute effects of different doses of mescaline and the role of the serotonin 5-HT2A receptor in mescaline-induced altered states of consciousness (MDR-Study). The study will be conducted at the University Hospital Basel Liechti Lab, in Basel, Switzerland, and is planned to start this month.
May 18, 2021 06:30 pm ET
The Chopra Foundation and MindMed Enter Into Letter of Intent to Partner on the Future of Psychedelic Medicines & Mental Wellbeing
NEW YORK, May 18, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) ("MindMed" or the "Company"), a leading clinical stage psychedelic medicine company, today announced it has entered into a letter of intent to partner with The Chopra Foundation to educate and build public awareness around the use of psychedelic medicines to treat mental illness, remove outdated stigmas, and ultimately research mental wellbeing approaches that can be used in psychedelic related psychotherapy.
May 17, 2021 07:30 am ET
MindMed Receives FDA Type C Meeting Response for Project Lucy Phase 2b Clinical Trial
MindMed Finalizes Clinical Development Approach for LSD Targeting Generalized Anxiety Disorder as Initial Indication
May 14, 2021 07:49 am ET
MindMed Announces Appointment of Dr. Sarah Y. Vinson as Additional Director
NEW YORK, May 14, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) ("MindMed" or the "Company") is pleased to announce that it has appointed Dr. Sarah Y. Vinson as a director of the Company and a member of its audit committee, effective immediately.
May 14, 2021 07:32 am ET
MindMed Announces 2021 Q1 Financial Results; Cash Balance of $160m USD ($194m CAD) to Execute on Diverse Clinical Pipeline
NEW YORK, May 14, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. ("MindMed'' or the "Company") (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic medicine biotech company, has announced its quarterly financial results for the quarter ended March 31, 2021.
May 13, 2021 07:30 am ET
MindMed Bolsters Management Team, Appoints Peter Mack PhD as Vice President of Pharmaceutical Development
NEW YORK, May 13, 2021 /CNW/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic-inspired medicine company has appointed Peter Mack PhD as Vice President of Pharmaceutical Development.
May 05, 2021 07:30 am ET
MindMed Announces Project Angie, Targeting the Treatment of Pain with Psychedelics
NEW YORK, May 5, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. ("MindMed" or the "Company") (NASDAQ: MNMD) (NEO: MMED), (DE: MMQ), a leading psychedelic-inspired medicine company announces the launch of its Project Angie to advance the development of psychedelics, including LSD, to treat pain conditions. MindMed is currently exploring two primary clinical indications for the treatment of pain.
May 04, 2021 10:07 am ET
IIROC Trade Resumption - MMED
TORONTO, May 4, 2021 /CNW/ - Trading resumes in:
May 04, 2021 10:01 am ET
IIROC Trading Halt - MMED
TORONTO, May 4, 2021 /CNW/ - The following issues have been halted by IIROC:
Apr 27, 2021 10:36 am ET
IIROC Trade Resumption - MMED
TORONTO, April 27, 2021 /CNW/ - Trading resumes in:
Apr 27, 2021 10:31 am ET
IIROC Trading Halt - MMED
TORONTO, April 27, 2021 /CNW/ - The following issues have been halted by IIROC:
Apr 27, 2021 10:17 am ET
IIROC Trade Resumption - MMED
TORONTO, April 27, 2021 /CNW/ - Trading resumes in:
Apr 27, 2021 10:10 am ET
IIROC Trading Halt - MMED
TORONTO, April 27, 2021 /CNW/ - The following issues have been halted by IIROC:
Apr 27, 2021 07:30 am ET
MindMed Begins Trading on Nasdaq
NEW YORK, April 27, 2021 /CNW/ -- MindMed (Nasdaq: MNMD, NEO: MMED, DE: MMQ), a leading psychedelic medicine biotech company, is pleased to announce the start of trading on The Nasdaq Capital Market ("Nasdaq"). Trading will begin on Tuesday, April 27, 2021, under the symbol "MNMD" on the Nasdaq.
Apr 26, 2021 09:48 am ET
IIROC Trade Resumption - MMED
TORONTO, April 26, 2021 /CNW/ - Trading resumes in:
Apr 26, 2021 09:42 am ET
IIROC Trading Halt - MMED
TORONTO, April 26, 2021 /CNW/ - The following issues have been halted by IIROC:
Apr 23, 2021 07:30 am ET
MindMed To Commence Trading on Nasdaq
NEW YORK, April 23, 2021 /CNW/ -- MindMed (Nasdaq: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic medicine biotech company, announced today that the Company's subordinate voting shares have been approved for listing on The Nasdaq Capital Market ("Nasdaq"). Trading is expected to begin on Tuesday, April 27, 2021, under the symbol "MNMD" on the Nasdaq.  MindMed will retain its listing on the Neo Exchange Inc. under the symbol "MMED" and the Company's subordinate voting shares will continue to trade on the OTCQB under the symbol "MMEDF" until trading on the Nasdaq commences.
Apr 05, 2021 07:30 am ET
MindMed Announces the Publication of New Data on Personalized MDMA Dosing
BASEL, Switzerland, April 5, 2021 /CNW/ -- MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading clinical-stage psychedelic medicine biotech company, announced the publication of the first study on MDMA dosing optimization using personalized medicine. The study took place at the University Hospital Basel Liechti Lab, in Basel, Switzerland. This study provides the first scientific data for predicting responses to MDMA and optimizing dosing. This may maximize the potential beneficial therapeutic effects while reducing adverse responses when treating medical conditions.
Mar 30, 2021 05:32 pm ET
MindMed Announces Filing of Preliminary Base Shelf Prospectus and F-10 with the SEC under MJDS
TORONTO, March 30, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. ("MindMed" or the "Company") (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ) is pleased to announce that it has filed a new preliminary short form base shelf prospectus (the "Base Shelf Prospectus") with securities regulators in each of the provinces and territories of Canada, and a corresponding registration statement on Form F–10 (the "Registration Statement") with the United States Securities and Exchange Commission ("SEC") in accordance with the Multijurisdictional Disclosure System established between Canada and the United States.
Mar 30, 2021 07:30 am ET
Mar 29, 2021 07:30 am ET
MindMed Announces the Addition of Stanford University Neuroscientist as Chair of the Scientific Advisory Board
Dr. Robert C. Malenka is the Pritzker Professor of Psychiatry and Behavioral Sciences, Director of the Nancy Pritzker Laboratory and Deputy Director of the Wu Tsai Neurosciences Institute at Stanford University
Mar 22, 2021 08:00 am ET
NEO Exchange Announces Inclusion in FTSE Russell Indexes
NEO is proud to announce that FTSE Russell, the global index, data, and analytics provider, now recognizes the N
Mar 22, 2021 07:30 am ET
MindMed Announces Inclusion in FTSE Russell Indexes
NEW YORK, March 22, 2021 /CNW/ -- MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company announced that effective as of Friday March 19th, 2021, MindMed has been added to the FTSE Global Micro-Cap Index (which represents $1.3 trillion in global market cap) and the FTSE Total-Cap index (which represents $54.7 trillion in global market cap).
Mar 09, 2021 01:23 pm ET
MindMed Increases Cash on Hand to CAD $205.2m (USD $162m), Closes Financing of CAD $19.5m (USD $15.4m)
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Mar 08, 2021 06:07 am ET
MindMed Announces C$19.5 Million Bought Deal Private Placement Offering
/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./
Mar 05, 2021 10:13 am ET
IIROC Trade Resumption - MMED
TORONTO, March 5, 2021 /CNW/ - Trading resumes in:
Mar 05, 2021 09:58 am ET
IIROC Trading Halt - MMED
TORONTO, March 5, 2021 /CNW/ - The following issues have been halted by IIROC:
Feb 26, 2021 12:48 pm ET
MindMed Closes Acquisition of HealthMode, a Leading Machine Learning Digital Medicine Company
Acquisition will help build a full stack digital mental health platform for psychedelic medicines; Ex-Pfizer Digital Medicine Executive Dr. Daniel R. Karlin and former Google AI/ML industry veteran Bradford Cross added to MindMed executive team
Feb 18, 2021 06:30 am ET
MindMed Reaches Agreement to Acquire HealthMode, a Leading Machine Learning Digital Medicine Company
Acquisition will help build a full stack digital mental health platform for psychedelic medicines; Ex-Pfizer Digital Medicine Executive Dr. Daniel R. Karlin M.D. M.A. and former Google AI/ML industry veteran Bradford Cross added to MindMed executive team 
Feb 18, 2021 06:30 am ET
MindMed Reaches Agreement to Acquire HealthMode, a Leading Machine Learning Digital Medicine Company
Acquisition will help build a full stack digital mental health platform for psychedelic medicines; Ex-Pfizer Digital Medicine Executive Dr. Daniel R. Karlin M.D. M.A. and former Google AI/ML industry veteran Bradford Cross added to MindMed executive team 
Feb 17, 2021 06:30 am ET
MindMed's LSD Neutralizer Study Begins
Potential Emergency Off-Switch for Psychedelic Assisted Therapies
Feb 17, 2021 06:30 am ET
MindMed's LSD Neutralizer Study Begins
Potential Emergency Off-Switch for Psychedelic Assisted Therapies
Feb 02, 2021 06:30 am ET
MindMed Streamlines Leadership with Further Emphasis on Integrating Psychedelic Drug Development with Digital Medicines and Therapeutics
J.R. Rahn to become sole CEO; Perry Dellelce to become Chair; Stephen Hurst retires as executive but remains on board; Stanley Glick retires as board member
Feb 02, 2021 06:30 am ET
MindMed Streamlines Leadership with Further Emphasis on Integrating Psychedelic Drug Development with Digital Medicines and Therapeutics
J.R. Rahn to become sole CEO; Perry Dellelce to become Chair; Stephen Hurst retires as executive but remains on board; Stanley Glick retires as board member
Jan 20, 2021 06:30 am ET
MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA and LSD
BASEL, Switzerland, Jan. 20, 2021 /CNW/ -- MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company, announced today the start of the first ever clinical trial measuring and evaluating MDMA and LSD used in combination in the human body. The trial will be conducted at the University Hospital Basel Liechti Lab, in Basel, Switzerland.
Jan 20, 2021 06:30 am ET
MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA and LSD
BASEL, Switzerland, Jan. 20, 2021 /PRNewswire/ -- MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company, announced today the start of the first ever clinical trial measuring and evaluating MDMA and LSD used in combination in the human body. The trial will be conducted at the University Hospital Basel Liechti Lab, in Basel, Switzerland.
Jan 14, 2021 06:30 am ET
MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience
Psychedelic Pharmaceutical Scientist and Clinical Pharmacologist Robert Barrow Appointed as Chief Development Officer
Jan 14, 2021 06:30 am ET
MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience
Psychedelic Pharmaceutical Scientist and Clinical Pharmacologist Robert Barrow Appointed as Chief Development Officer
Jan 12, 2021 06:30 am ET
MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers
MindMed to Commence Groundbreaking LSD Microdosing Study Evaluating Benefits on Neuroplasticity, Sleep, Cognitive Enhancement Variables and Immune System Response on the Human Body
Jan 12, 2021 06:30 am ET
MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers
MindMed to Commence Groundbreaking LSD Microdosing Study Evaluating Benefits on Neuroplasticity, Sleep, Cognitive Enhancement Variables and Immune System Response on the Human Body
Jan 07, 2021 07:56 am ET
Jan 04, 2021 04:00 pm ET
MindMed Files Final Prospectus In Connection With Bought Deal Equity Financing
FINANCING TO SUPPORT THE DEVELOPMENT OF MINDMED'S DIGITAL MEDICINE DIVISION AND PSYCHEDELIC INSPIRED MEDICINES AND EXPERIENTIAL THERAPIES
Dec 21, 2020 04:00 pm ET
MindMed Files Preliminary Prospectus In Connection With Bought Deal Equity Financing
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Dec 15, 2020 10:08 am ET
MindMed Upsizes Previously Announced Bought Deal Public Offering
/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./
Dec 15, 2020 09:31 am ET
IIROC Trade Resumption - MMED
TORONTO, Dec. 15, 2020 /CNW/ - Trading resumes in:
Dec 15, 2020 09:29 am ET
IIROC Trading Halt - MMED
TORONTO, Dec. 15, 2020 /CNW/ - The following issues have been halted by IIROC:
Dec 14, 2020 07:09 pm ET
MindMed Announces $50 Million Bought Deal Public Offering
/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./
Dec 14, 2020 02:16 pm ET
IIROC Trade Resumption - MMED
TORONTO, Dec. 14, 2020 /CNW/ - Trading resumes in:
Dec 14, 2020 02:08 pm ET
IIROC Trading Halt - MMED
TORONTO, Dec. 14, 2020 /CNW/ - The following issues have been halted by IIROC:
Dec 14, 2020 06:30 am ET
Dec 14, 2020 06:30 am ET
Dec 11, 2020 07:39 am ET
MindMed Closes Upsized Financing of CAD $34.5m, Gross Proceeds Raised Since Company Founding Now Total CAD $121.4m (USD $94.8m)
Post-Financing Cash Reserves of CAD $85m (USD $66.4m) to Enable Advancement of Digital Therapeutics Division and Growing Clinical Trial Pipeline
Dec 08, 2020 04:00 pm ET
MindMed Files Final Prospectus In Connection With Bought Deal Equity Financing
Financing To Support The Development Of MindMed's Digital Medicine Division And Psychedelic Inspired Medicines And Experiential Therapies
Nov 30, 2020 03:30 pm ET
MindMed Files Preliminary Prospectus In Connection With Bought Deal Equity Financing
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Nov 25, 2020 11:38 am ET
MindMed Upsizes Previously Announced Bought Deal Public Offering
/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./
Nov 25, 2020 07:30 am ET
MindMed Announces $25 Million Bought Deal Public Offering
/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./
Nov 24, 2020 06:30 am ET
MindMed to Launch Albert, A Digital Medicine Division for Psychedelic Medicines
NEW YORK, Nov. 24, 2020 /CNW/ -- MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading psychedelic medicine biotech company, is establishing a digital medicine division known as Albert. Albert is in the process of assembling and recruiting a leading team of technologists, therapists, and clinical drug development experts to help the company research, develop and build an integrated technical platform and comprehensive toolset aimed at delivering psychedelic inspired medicines and experiential therapies combined with digital therapeutics.
Nov 24, 2020 06:30 am ET
MindMed to Launch Albert, A Digital Medicine Division for Psychedelic Medicines
NEW YORK, Nov. 24, 2020 /PRNewswire/ -- MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading psychedelic medicine biotech company, is establishing a digital medicine division known as Albert. Albert is in the process of assembling and recruiting a leading team of technologists, therapists, and clinical drug development experts to help the company research, develop and build an integrated technical platform and comprehensive toolset aimed at delivering psychedelic inspired medicines and experiential therapies combined with digital therapeutics.
Nov 16, 2020 06:30 am ET
MindMed Receives Approval of Protocol Design to Evaluate Microdoses of LSD For Adult ADHD In Phase 2a Clinical Trial from Swiss and Dutch Health Authorities
Project Lucy Submits Pre-IND Briefing Package to the FDA; Agrees Q1 Interim Analysis of Swiss Phase 2a Trial of LSD Assisted Therapy for Anxiety Disorders
Nov 16, 2020 06:30 am ET
MindMed Receives Approval of Protocol Design to Evaluate Microdoses of LSD For Adult ADHD In Phase 2a Clinical Trial from Swiss and Dutch Health Authorities
Project Lucy Submits Pre-IND Briefing Package to the FDA; Agrees Q1 Interim Analysis of Swiss Phase 2a Trial of LSD Assisted Therapy for Anxiety Disorders
Nov 13, 2020 05:20 pm ET
MindMed Announces Q3 2020 Financial Results;
TORONTO, Nov 13, 2020 /CNW/ -- MindMed (NEO: MMED) (OTCQB: MMEDF), a leading psychedelic medicine biotech company, has announced its third quarter financial results for the three and nine months ended September 30, 2020. 
Nov 13, 2020 05:20 pm ET
MindMed Announces Q3 2020 Financial Results;
TORONTO, Nov 13, 2020 /PRNewswire/ -- MindMed (NEO: MMED) (OTCQB: MMEDF), a leading psychedelic medicine biotech company, has announced its third quarter financial results for the three and nine months ended September 30, 2020. 
Nov 02, 2020 06:30 am ET
MindMed Announces the Completion of Phase 1 Study Measuring Dosing Effects of LSD
Data to Support MindMed's Project Lucy in Preparing Phase 2b Trial for Anxiety Disorders
Nov 02, 2020 06:30 am ET
MindMed Announces the Completion of Phase 1 Study Measuring Dosing Effects of LSD
Data to Support MindMed's Project Lucy in Preparing Phase 2b Trial for Anxiety Disorders
Oct 30, 2020 09:17 am ET
MindMed Closes Upsized Financing of CAD $28.75m With Strong Institutional Demand for Psychedelic Medicines
Post-Financing Cash Reserves of CAD $50.1m (USD $37.8m) to Enable Continued Advancement of Diverse and Growing Clinical Trial Pipeline of Psychedelics
Oct 27, 2020 04:30 pm ET
MindMed Files Final Prospectus In Connection With Bought Deal Equity Financing
FINANCING TO SUPPORT THE DEVELOPMENT OF MINDMED'S GROWING PIPELINE OF PSYCHEDELIC INSPIRED MEDICINES AND EXPERIENTIAL THERAPIES
Oct 16, 2020 04:30 pm ET
MindMed Files Preliminary Prospectus In Connection With Bought Deal Equity Financing
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Oct 09, 2020 08:28 am ET
MindMed Announces $25 Million Bought Deal Public Offering
/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./
Oct 05, 2020 05:00 am ET
MindMed Partners with NYU Langone Medical Center to Launch Groundbreaking Training Program for Psychedelic Therapies and Medicines
MindMed To Provide Funding for Psychedelic Medicine Research Training Program at NYU Langone Health and NYU Grossman School of Medicine  
Sep 24, 2020 07:30 am ET
MindMed and Liechti Lab Announce R&D Collaboration On Psilocybin
MindMed Collaborating On Study Comparing Effects Induced By LSD and Psilocybin Under Exclusive License Agreement With University Hospital Basel Liechti Lab
Sep 23, 2020 11:39 am ET
MindMed Confirms No Material Change
NEW YORK, Sept. 23, 2020 /CNW/ -- Mind Medicine (MindMed) Inc. (NEO: MMED)(OTCQB: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines announces, at the request of IIROC on behalf of the NEO Exchange, that MindMed's management is unaware of any material change in MindMed's operations that would account for the recent increase in market activity.
Sep 21, 2020 07:30 am ET
MindMed Submits Application For NASDAQ Up-Listing, Appoints Canaccord Genuity As Financial Advisor
NEW YORK, Sept. 21, 2020 /CNW/ -- Mind Medicine (MindMed) Inc. (NEO: MMED)(OTCQB: MMEDF)(DE: MMQ), the leading drug development company for psychedelic inspired medicines, is evaluating an expanded United States investor base through an up-listing on the NASDAQ Capital Market ("NASDAQ").
Aug 25, 2020 07:30 am ET
MindMed Announces First-Ever Clinical Trial Combining MDMA and LSD
MindMed is funding a Phase 1 Clinical Trial at University Hospital Basel Liechti Lab
Aug 20, 2020 08:03 pm ET
/C O R R E C T I O N -- Mind Medicine (MindMed) Inc./
In the news release, Mind Medicine (MindMed) Inc. Announces Q2 2020 Financial Results, issued 14-Aug-2020 by Mind Medicine (MindMed) Inc. over PR Newswire, we are advised by the company that the second bullet of the Financial Highlights (in USD) section should read "Net and comprehensive loss of $5.8 million for the three months ended June 30, 2020" rather than "Net and comprehensive loss of $5.8 million for the six months ended June 30, 2020" as originally issued inadvertently. The complete, corrected release follows:
Aug 14, 2020 07:00 am ET
Mind Medicine (MindMed) Inc. Announces Q2 2020 Financial Results
NEW YORK, Aug. 14, 2020 /CNW/ -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading psychedelic pharmaceutical company, has announced its second quarter financial results for the three and six months ended June 30, 2020. 
Aug 13, 2020 07:30 am ET
MindMed Expanding R&D in Europe, Appoints Dr. Miri Halperin Wernli As President
BASEL, Switzerland, Aug. 13, 2020 /CNW/ -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF) is expanding its presence in Europe. The leading neuro-pharmaceutical company for psychedelic inspired medicines will open an operating subsidiary in Switzerland that will oversee clinical development, scientific collaborations and the expansion of MindMed's business in Europe. As part of the ramp up and planning process for its growing global pipeline of clinical programs of psychedelic inspired medicines, MindMed's board of directors has appointed Dr. Miri Halperin Wernli as President to help g
Aug 10, 2020 08:35 am ET
Venture Company Investor Presentations Now Available for On-Demand Viewing
Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations
Aug 06, 2020 07:30 am ET
MindMed Adds Psychedelic Assisted Therapy Expert Dr. Peter Gasser As Clinical Advisor For Project Lucy
Applauds Health Canada's Approval Of Psilocybin Compassionate Access For Patients
Aug 06, 2020 07:30 am ET
MindMed Adds Psychedelic Assisted Therapy Expert Dr. Peter Gasser As Clinical Advisor For Project Lucy
Applauds Health Canada's Approval Of Psilocybin Compassionate Access For Patients
Aug 03, 2020 02:30 pm ET
Live Investor Conference & Webinar: Venture Companies Present August 6th
NEW YORK, Aug. 3, 2020 /PRNewswire/ -- Virtual Investor Conferences today announced the agenda for the upcoming OTCQB Venture Virtual lnvestor Conference, the leading proprietary investor conference series.  Individual investors, institutional investors, advisors and analysts are invited to attend. The program opens at 9:15 AM ET on Thursday, August 6th with the first live webcast at 9:30 AM ET.
Aug 03, 2020 02:21 pm ET
Live Investor Conference & Webinar: Venture Companies Present August 6th
Company executives will share vision and answer audience questions at VirtualInvestorConferences.com
Jul 28, 2020 07:30 am ET
MindMed Completes Dosing 18-MC Phase 1 Study
NEW YORK, July 28, 2020 /CNW/ -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading psychedelic pharmaceutical company, has concluded dosing in a Phase 1 Single Ascending Dose (SAD) study of 18-MC. The dosing of 18-MC was well tolerated in humans and will help advance planning for a Phase 2a clinical trial in opioid addiction. Further, the study has not  incurred any delays due to the COVID-19 pandemic and the Multiple Ascending Dose (MAD) study is on track according to the original development timeline.
Jul 28, 2020 07:30 am ET
MindMed Completes Dosing 18-MC Phase 1 Study
NEW YORK, July 28, 2020 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading psychedelic pharmaceutical company, has concluded dosing in a Phase 1 Single Ascending Dose (SAD) study of 18-MC. The dosing of 18-MC was well tolerated in humans and will help advance planning for a Phase 2a clinical trial in opioid addiction. Further, the study has not  incurred any delays due to the COVID-19 pandemic and the Multiple Ascending Dose (MAD) study is on track according to the original development timeline.
Jun 26, 2020 05:41 pm ET
MindMed Building Diverse Pipeline and Leadership Position in Psychedelic Inspired Medicines Industry
MindMed Co-founders and Co-CEOs JR Rahn and Stephen Hurst to provide corporate update of activities and investor Q&A on July 2, 2020 at 1pm EDT
Jun 26, 2020 05:41 pm ET
MindMed Building Diverse Pipeline and Leadership Position in Psychedelic Inspired Medicines Industry
MindMed Co-founders and Co-CEOs JR Rahn and Stephen Hurst to provide corporate update of activities and investor Q&A on July 2, 2020 at 1pm EDT
Jun 24, 2020 12:05 am ET
MindMed Developing IP For Personalized Psychedelic Assisted Therapies
MindMed, in collaboration with the University Hospital Basel, has filed two separate patent applications for technologies to screen and optimize the dosing of MDMA and LSD
Jun 24, 2020 12:05 am ET
MindMed Developing IP For Personalized Psychedelic Assisted Therapies
MindMed, in collaboration with the University Hospital Basel, has filed two separate patent applications for technologies to screen and optimize the dosing of MDMA and LSD
Jun 18, 2020 07:00 am ET
MindMed To Evaluate Ayahuasca's Active Ingredient DMT In Phase 1 Clinical Trial Collaboration
Phase 1 Trial to experiment with dosing methods to better understand how humans react to DMT, setting stage for future potential Phase 2a proof of concept trials
Jun 18, 2020 07:00 am ET
MindMed To Evaluate Ayahuasca's Active Ingredient DMT In Phase 1 Clinical Trial Collaboration
Phase 1 Trial to experiment with dosing methods to better understand how humans react to DMT, setting stage for future potential Phase 2a proof of concept trials
Jun 08, 2020 07:00 am ET
Phase 2 Clinical Trial of LSD for "Suicide Headaches" Begins Treating Patients
MindMed Is Collaborating on a Phase 2 Clinical Trial of LSD For Cluster Headaches with University Hospital Basel's Liechti Lab
Jun 08, 2020 07:00 am ET
Phase 2 Clinical Trial of LSD for "Suicide Headaches" Begins Treating Patients
MindMed Is Collaborating on a Phase 2 Clinical Trial of LSD For Cluster Headaches with University Hospital Basel's Liechti Lab
Jun 04, 2020 07:00 am ET
MindMed Launches Project Lucy Focused on LSD Experiential Therapy For Anxiety Disorders
Targeting a Phase 2b psychedelic assisted therapy trial for the treatment of anxiety disorders
Jun 04, 2020 07:00 am ET
MindMed Launches Project Lucy Focused on LSD Experiential Therapy For Anxiety Disorders
Targeting a Phase 2b psychedelic assisted therapy trial for the treatment of anxiety disorders
Jun 02, 2020 07:00 am ET
MindMed's Microdosing Division Further Expands Phase 2 Clinical Trial of Microdosing LSD For Adult ADHD
BASEL, Switzerland, June 2, 2020 /CNW/ -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF) is expanding its Phase 2a clinical trial of LSD microdosing for Adult ADHD. MindMed is the leading neuro-pharmaceutical company for psychedelic inspired medicines and as part of its expanding slate of research and clinical trials, will add an additional clinical trial site and Principal Investigator at the University Hospital Basel in Basel, Switzerland, the birthplace of LSD for its Phase 2a clinical trial of LSD microdosing.
Jun 02, 2020 07:00 am ET
MindMed's Microdosing Division Further Expands Phase 2 Clinical Trial of Microdosing LSD For Adult ADHD
BASEL, Switzerland, June 2, 2020 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF) is expanding its Phase 2a clinical trial of LSD microdosing for Adult ADHD. MindMed is the leading neuro-pharmaceutical company for psychedelic inspired medicines and as part of its expanding slate of research and clinical trials, will add an additional clinical trial site and Principal Investigator at the University Hospital Basel in Basel, Switzerland, the birthplace of LSD for its Phase 2a clinical trial of LSD microdosing.
May 27, 2020 07:00 am ET
MindMed Adds MDMA to Develop Next-Gen Psychedelic Therapies
NEW YORK, May 27, 2020 /CNW/ -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines, is now adding the psychedelic compound MDMA to its R&D pipeline.
May 27, 2020 07:00 am ET
MindMed Adds MDMA to Develop Next-Gen Psychedelic Therapies
NEW YORK, May 27, 2020 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NEO: MMED OTCQB: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines, is now adding the psychedelic compound MDMA to its R&D pipeline.
May 26, 2020 09:53 am ET
MindMed Closes Upsized Financing of $13.2m to Advance UHB Liechti Lab Collaboration for Next-Gen Psychedelic Inspired Medicines
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
May 21, 2020 06:50 pm ET
MindMed Files Final Prospectus In Connection With Bought Deal Equity Financing
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
May 14, 2020 07:00 am ET
MindMed Reports First Quarter 2020 Results and Corporate Update
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
May 12, 2020 07:00 am ET
MindMed Advances Phase 2 LSD Microdosing Trial For Adult ADHD, Appoints Principal Investigator
Signs Clinical Trial Agreement With Maastricht University In Netherlands
May 11, 2020 05:25 pm ET
MindMed Advances Phase 2 LSD Microdosing Trial For Adult ADHD, Appoints Principal Investigator
Signs Clinical Trial Agreement With Maastricht University In Netherlands
May 11, 2020 05:12 pm ET
MindMed Files Preliminary Prospectus In Connection With Bought Deal Equity Financing
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
May 06, 2020 07:15 am ET
MindMed Announces Increase in Bought Deal Offering to Approximately $11.5 Million
Mind Medicine (MindMed) Inc. (NEO: MMED, OTCQB: MMEDF) (“MindMed” or the “Company”) is pleased to announce that it has entered into an amended letter of engagement with Eight Capital, under which Eight Capital has now agreed to purchase 21,699,000...
May 05, 2020 07:00 am ET
MindMed Announces $10 Million Bought Deal Equity Financing to Fund University Hospital Basel Collaboration
Mind Medicine (MindMed) Inc. (NEO: MMED, OTCQB: MMEDF) (“MindMed” or the “Company”) is pleased to announce that it has entered into a letter of engagement with Eight Capital, under which Eight Capital has agreed to purchase, as sole bookrunner and...
Apr 22, 2020 06:00 am ET
Psychedelic Pharmaceutical Company MindMed Develops LSD Neutralizer Technology To Shorten and Stop LSD Trips
Advances Discovered in Collaboration with University Hospital Basel's Liechti Laboratory and Aims To Enhance Therapeutic Potential of Psychedelics
Apr 22, 2020 06:00 am ET
Psychedelic Pharmaceutical Company MindMed Develops LSD Neutralizer Technology To Shorten and Stop LSD Trips
Advances Discovered in Collaboration with University Hospital Basel's Liechti Laboratory and Aims To Enhance Therapeutic Potential of Psychedelics
Apr 21, 2020 04:05 pm ET
Psychedelic Pharmaceutical Company MindMed Develops LSD Neutralizer Technology To Shorten and Stop LSD Trips
Advances Discovered in Collaboration with University Hospital Basel's Liechti Laboratory and Aims To Enhance Therapeutic Potential of Psychedelics
Apr 21, 2020 04:05 pm ET
Psychedelic Pharmaceutical Company MindMed Develops LSD Neutralizer Technology To Shorten and Stop LSD Trips
Advances Discovered in Collaboration with University Hospital Basel's Liechti Laboratory and Aims To Enhance Therapeutic Potential of Psychedelics
Apr 20, 2020 05:00 am ET
MindMed Promotes Jeanne Bonelle to Executive Vice President, Technical Operations
Company is actively developing and scaling manufacturing processes for 18-MC and LSD APIs to be used in the company's future drug trials
Apr 20, 2020 05:00 am ET
MindMed Promotes Jeanne Bonelle to Executive Vice President, Technical Operations
Company is actively developing and scaling manufacturing processes for 18-MC and LSD APIs to be used in the company's future drug trials
Apr 17, 2020 08:00 am ET
REPEAT: MindMed Initiates Dosing in Human Safety Study of Novel Treatment for Opioid Addiction, 18-MC
NEW YORK, April 17, 2020 /CNW/ -- Mind Medicine (MindMed) Inc. (NEO: MMED)(OTC: MMEDF), the leading psychedelic pharmaceutical company, has begun dosing the first subject in an additional Phase 1 human safety trial of 18-MC. The safety trial has commenced on time and as scheduled, even during the COVID-19 pandemic. 18-MC is a proprietary, orally active, non-hallucinogenic molecule based on the psychedelic ibogaine.  
Apr 17, 2020 08:00 am ET
REPEAT: MindMed Initiates Dosing in Human Safety Study of Novel Treatment for Opioid Addiction, 18-MC
NEW YORK, April 17, 2020 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NEO: MMED)(OTC: MMEDF), the leading psychedelic pharmaceutical company, has begun dosing the first subject in an additional Phase 1 human safety trial of 18-MC. The safety trial has commenced on time and as scheduled, even during the COVID-19 pandemic. 18-MC is a proprietary, orally active, non-hallucinogenic molecule based on the psychedelic ibogaine.  
Apr 17, 2020 06:00 am ET
MindMed Announces U.S. Trading on the OTCQB Venture Market Under Symbol MMEDF
NEW YORK, April 17, 2020 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NEO: MMED; OTCQB: MMEDF) (the "Company" or "MindMed"), the leading psychedelic pharmaceutical company, is pleased to announce that the Company has graduated from the OTC Pink Open Market to the OTCQB Venture Market ("OTCQB"). MindMed's subordinate voting shares will commence trading on the OTCQB in the United States at the open of market on April 17, 2020 under the symbol "MMEDF". The Company's subordinate voting shares will continue to trade in Canada on the NEO Exchange under the symbol "MMED" and the quotation board of
Apr 16, 2020 09:57 pm ET
MindMed Initiates Dosing in Human Safety Study of Novel Treatment for Opioid Addiction, 18-MC
NEW YORK, April 16, 2020 /CNW/ -- Mind Medicine (MindMed) Inc. (NEO: MMED)(OTC: MMEDF), the leading psychedelic pharmaceutical company, has begun dosing the first subject in an additional Phase 1 human safety trial of 18-MC. The safety trial has commenced on time and as scheduled, even during the COVID-19 pandemic. 18-MC is a proprietary, orally active, non-hallucinogenic molecule based on the psychedelic ibogaine.  
Apr 16, 2020 09:57 pm ET
MindMed Initiates Dosing in Human Safety Study of Novel Treatment for Opioid Addiction, 18-MC
NEW YORK, April 16, 2020 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NEO: MMED)(OTC: MMEDF), the leading psychedelic pharmaceutical company, has begun dosing the first subject in an additional Phase 1 human safety trial of 18-MC. The safety trial has commenced on time and as scheduled, even during the COVID-19 pandemic. 18-MC is a proprietary, orally active, non-hallucinogenic molecule based on the psychedelic ibogaine.  
Apr 01, 2020 07:00 am ET
MindMed Acquires Exclusive License to Eight Clinical Trials of LSD, Partners with World-Leading Psychedelic Research Laboratory at University Hospital Basel
BASEL, Switzerland, April 1, 2020 /CNW/ -- Mind Medicine (MindMed) Inc. (NEO: MMED OTC: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines, today announced the signing of a multi-year, branch exclusive collaboration with the laboratory of Professor Dr. Matthias Liechti, the world-leading psychedelics pharmacology and clinical research group at University Hospital Basel in Switzerland.
Apr 01, 2020 07:00 am ET
MindMed Acquires Exclusive License to Eight Clinical Trials of LSD, Partners with World-Leading Psychedelic Research Laboratory at University Hospital Basel
BASEL, Switzerland, April 1, 2020 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NEO: MMED OTC: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines, today announced the signing of a multi-year, branch exclusive collaboration with the laboratory of Professor Dr. Matthias Liechti, the world-leading psychedelics pharmacology and clinical research group at University Hospital Basel in Switzerland.
Mar 30, 2020 06:21 pm ET
MindMed Reports Year-end Results and Corporate Update
NEW YORK, March 30, 2020 /CNW/ -- Mind Medicine (MindMed) Inc. (NEO: MMED OTC: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines, today announced the release of its audited consolidated financial statements (the "Financial Statements") and accompanying management's discussion and analysis (the "MD&A") for the period from May 30, 2019, date of incorporation, to December 31, 2019 (the "period ended December 31, 2019"). All financial figures contained herein are expressed in U.S. dollars ("USD") unless otherwise noted.
Mar 30, 2020 06:21 pm ET
MindMed Reports Year-end Results and Corporate Update
NEW YORK, March 30, 2020 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NEO: MMED OTC: MMEDF), the leading neuro-pharmaceutical company for psychedelic inspired medicines, today announced the release of its audited consolidated financial statements (the "Financial Statements") and accompanying management's discussion and analysis (the "MD&A") for the period from May 30, 2019, date of incorporation, to December 31, 2019 (the "period ended December 31, 2019"). All financial figures contained herein are expressed in U.S. dollars ("USD") unless otherwise noted.
Mar 25, 2020 06:00 am ET
MindMed Advances 18-MC, Potential Treatment for Opioid Addiction, Into Further Clinical Testing
Company continues research, without interruption, and on schedule
Mar 25, 2020 06:00 am ET
MindMed Advances 18-MC, Potential Treatment for Opioid Addiction, Into Further Clinical Testing
Company continues research, without interruption, and on schedule
Mar 12, 2020 06:00 am ET
Leading Psychedelic Pharmaceutical Company MindMed Forms New Board Committee To Evaluate Acquisitions And Scientific Collaborations
John Hopkins professor and psychedelics expert Matthew Johnson to act as senior advisor to committee
Mar 03, 2020 08:00 am ET
MindMed Lists on NEO to Become World’s First Psychedelic Pharmaceutical Company to Go Public
NEO is pleased to announce it has granted final approval to Mind Medicine (MindMed) Inc.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.